IGMS Quote, Financials, Valuation and Earnings

BioXcel Therapeutics has a net margin of -8894.9% compared to IGM Biosciences's net margin of -6378.51%. IGM Biosciences's return on equity of -159.45% beat BioXcel Therapeutics's return on equity of --.

IGM Biosciences has a consensus price target of $1.88, signalling upside risk potential of 42.05%. On the other hand BioXcel Therapeutics has an analysts' consensus of $48.00 which suggests that it could grow by 1838.5%. Given that BioXcel Therapeutics has higher upside potential than IGM Biosciences, analysts believe BioXcel Therapeutics is more attractive than IGM Biosciences.

IGM Biosciences has a beta of 0.579, which suggesting that the stock is 42.126% less volatile than S&P 500. In comparison BioXcel Therapeutics has a beta of 0.640, suggesting its less volatile than the S&P 500 by 36.034%.

IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioXcel Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. BioXcel Therapeutics pays out -- of its earnings as a dividend.

IGM Biosciences quarterly revenues are $412K, which are larger than BioXcel Therapeutics quarterly revenues of $214K. IGM Biosciences's net income of -$36.6M is lower than BioXcel Therapeutics's net income of -$13.7M. Notably, IGM Biosciences's price-to-earnings ratio is -- while BioXcel Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 29.82x versus 2.09x for BioXcel Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -8894.9% compared to IGM Biosciences's net margin of -49.65%. IGM Biosciences's return on equity of -159.45% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

IGM Biosciences has a consensus price target of $1.88, signalling upside risk potential of 42.05%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that NovaBay Pharmaceuticals has higher upside potential than IGM Biosciences, analysts believe NovaBay Pharmaceuticals is more attractive than IGM Biosciences.

IGM Biosciences has a beta of 0.579, which suggesting that the stock is 42.126% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

IGM Biosciences quarterly revenues are $412K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IGM Biosciences's net income of -$36.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, IGM Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 29.82x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -8894.9% compared to IGM Biosciences's net margin of --. IGM Biosciences's return on equity of -159.45% beat Palatin Technologies's return on equity of --.

IGM Biosciences has a consensus price target of $1.88, signalling upside risk potential of 42.05%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3281.64%. Given that Palatin Technologies has higher upside potential than IGM Biosciences, analysts believe Palatin Technologies is more attractive than IGM Biosciences.

IGM Biosciences has a beta of 0.579, which suggesting that the stock is 42.126% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

IGM Biosciences quarterly revenues are $412K, which are larger than Palatin Technologies quarterly revenues of --. IGM Biosciences's net income of -$36.6M is higher than Palatin Technologies's net income of --. Notably, IGM Biosciences's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 29.82x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -8894.9% compared to IGM Biosciences's net margin of --. IGM Biosciences's return on equity of -159.45% beat Theriva Biologics's return on equity of --.

IGM Biosciences has a consensus price target of $1.88, signalling upside risk potential of 42.05%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 322.27%. Given that Theriva Biologics has higher upside potential than IGM Biosciences, analysts believe Theriva Biologics is more attractive than IGM Biosciences.

IGM Biosciences has a beta of 0.579, which suggesting that the stock is 42.126% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

IGM Biosciences quarterly revenues are $412K, which are larger than Theriva Biologics quarterly revenues of --. IGM Biosciences's net income of -$36.6M is lower than Theriva Biologics's net income of -$4.4M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 29.82x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.